Clinical Trials Logo

Sleep Apnea, Obstructive clinical trials

View clinical trials related to Sleep Apnea, Obstructive.

Filter by:

NCT ID: NCT05091164 Completed - Clinical trials for Obstructive Sleep Apnea Syndrome

Feasibility Study of Sleep Endoscopy Under Hypnosis in a Sleep Center

DISE
Start date: February 8, 2021
Phase: N/A
Study type: Interventional

It is proposed to induce in a obstructive sleep apnea syndrome patient, a hypnotic trance leading to intense muscle relaxation, capable of reproducing in the upper airways (VAS) the muscle relaxation observed in sleep, at the origin of obstructive apnea and snoring. The collapsibility type obtained, classified according to Kezirian, will allow specific management by OAM in the event of predominant anteroposterior stenosis. There are no risks fort the patient. The Drug Induce Sleep endoscopy (DISE) is a fibroscopy of upper aerodigestive tract.

NCT ID: NCT05087316 Completed - Clinical trials for Mild Obstructive Sleep Apnea

Therapy of Oral Appliance for Adults Jordanians With Obstructive Sleep Apnea

TOAAJOSA
Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Introduction: Obstructive Sleep Apnea (OSA) is the most common form of sleep disordered breathing. Patients who arrive at the dental office with a diagnosis of OSA are often treated with a mandibular advancement device (MAD). A biomimetic oral appliance therapy (BOAT), offers an alternative non-surgical method, which can putatively resolve OSA by combined maxilla-mandibular correction, and addressing craniofacial deficiencies. The aim: To determine whether maxilla-mandibular correction changes induced by BOAT produce a more favorable upper airway, which might result in a reduction in the severity of OSA. Protocol: Adults who underwent an overnight sleep study and were diagnosed by a sleep specialist physician will be potential subjects for the current study. The BQ and EES will be recorded pre- and post- BOAT treatment. Subjects with mild to moderate OSA will have 2 months follow up visits and a final overnight sleep study to measure apnea-hypopnea index (AHI). The subjects will be asked to wear the appliance for 10-12 hours/day and at night. Findings will be analyzed statistically using paired t-tests.

NCT ID: NCT05077748 Recruiting - Clinical trials for Obstructive Sleep Apnea

An 18-year Follow-up Study on OSA in a Population-based Cohort

Start date: October 20, 2021
Phase:
Study type: Observational

Our research team has established a polysomnography (PSG) quantified population-based paediatric sleep cohort in 2003 for a childhood OSA prevalence study. Subjects were recruited from 13 randomly selected primary schools. All subjects from this original cohort will be invited to join this 18-year follow-up study to repeat the following data collection: questionnaires, anthropometric measurement, sleep study, 24-hour ambulatory blood pressure (ABP) measurement, echocardiography and neurocognitive assessment.

NCT ID: NCT05074056 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Ketorolac on Postoperative Pain Reduction in Pediatric Patients With Adenotonsillectomy

Start date: February 8, 2022
Phase: Phase 4
Study type: Interventional

Postoperative pain management in the pediatric patient undergoing tonsillectomy is challenging. Despite being used in many procedures for postoperative pain management, perioperative ketorolac usage in pediatric tonsillectomy surgery is very limited. A recent survey showed that only 8.2% of anesthesiologists use NSAIDS for perioperative management of children with OSA undergoing adenotonsillectomy. We propose to conduct a prospective, randomized study to investigate the opioid-sparing effect of perioperative ketorolac in pediatric patients who undergo tonsillectomies.

NCT ID: NCT05071612 Completed - Clinical trials for OSA - Obstructive Sleep Apnea

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

MARIPOSA
Start date: November 29, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.

NCT ID: NCT05067088 Recruiting - Clinical trials for Obstructive Sleep Apnea

Novel physIologiC prEdictors of Positive Airway Pressure Effectiveness

NICEPAP
Start date: January 1, 2022
Phase:
Study type: Observational

Millions of Americans suffer from high blood pressure, diabetes, strokes and motor vehicle accidents due to ineffective treatment of obstructive sleep apnea (OSA). Our preliminary data suggest that physiological causes of OSA such as easy arousability (low arousal threshold) or unstable breathing control (high loop gain) may influence effectiveness of OSA's most common treatment, continuous positive airway pressure (CPAP). The NICE-PAP study will examine how the physiologic traits that cause OSA in each individual impact CPAP effectiveness and can lead to personalized OSA treatments that improve patient lives.

NCT ID: NCT05057975 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Validation of an Integrated Digital Solution (SUNrise®) Versus Polysomnography for Obstructive Sleep Apnea Diagnosis

SUNSAS
Start date: October 28, 2021
Phase: N/A
Study type: Interventional

Validation of an integrated digital solution (SUNrise®) of mandibular movement automatic analysis by artificial intelligence versus polysomnography for obstructive sleep apnea diagnosis: a prospective, randomized, parallel-arm, open-label, multicenter, national, controlled study.

NCT ID: NCT05056766 Completed - Clinical trials for Sleep Apnea, Obstructive

How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement

OAMMM
Start date: September 1, 2021
Phase:
Study type: Observational

The OAMMM study is a mono-centrer , non interventional, prospective study, carried out in CH Valence Oral Appliance is indicated for first line moderate sleep Apnea Syndrome or severe sleep Apnea Syndrome after failure of positive airway pressure (CPAP). Clinical impact of each mm advancement of Oral Appliance is imperfectly assessed. The study aim to assess clinical and paraclinical efficacy of an oral Appliance on each mm of advancement.

NCT ID: NCT05055271 Completed - Clinical trials for Obstructive Sleep Apnea

Delphi Consensus Excessive Daytime Sleepiness in OSA

Start date: April 1, 2021
Phase:
Study type: Observational

The objective of this study is to generate expert consensus statements on the differential diagnosis, definition, and management of EDS in patients with OSA who are adequately treated with primary therapy.

NCT ID: NCT05053685 Recruiting - Clinical trials for Obstructive Sleep Apnea

Metanephrines in Obstructive Sleep Apnoea

Start date: July 29, 2020
Phase:
Study type: Observational

Although most patients have essential (unexplained) hypertension, some patients have a treatable underlying condition. One such condition is phaeochromocytoma, a tumour that produces excessive stress hormones. Left undiagnosed, patients may develop a hypertensive crisis that can be fatal. Measurements of stress hormones (both 24-hour urine collection and morning blood tests) are highly sensitive for detecting these tumours. However, these stress hormones may also be elevated in obstructive sleep apnoea (OSA) which affects 1 in 5 adults. The investigators hypothesize that in patients with OSA, blood tests will be better than 24-hr urine tests at ruling out a tumour. If this is confirmed, then OSA patients with suspected phaeochromocytoma could be investigated with a morning blood test instead of a traditional urine test, reducing unnecessary additional tests and patient anxiety. In this single site study, the investigators plan to recruit 70 patients undergoing polysomnography. 24hr urine and bloods will be measured. Patients with elevated hormone levels will undergo imaging to rule out a tumour. The primary outcome will be the accuracy of each test in ruling out a tumour. The secondary outcomes will be the relationship between stress hormone level and severity of OSA, which may help to explain the increased cardiovascular risk in patients with OSA, and the change in stress hormone level with treatment for OSA